Latest From Lupin Ltd.
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.
Walgreen and other retailers allege no-authorized generic patent settlement for extended-release metformin allowed Santarus (Valeant) to block generic entry for four years while raising the price more than 750%.
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
- Controlled Release
- Generic Drugs
- Drug Delivery
- Therapeutic Areas
- Lupin Laboratories
- Parent & Subsidiaries
- Lupin Ltd.
- Senior Management
Vinita Gupta, CEO
Ramesh Swaminathan , CFO
- Contact Info
Phone: (91) 22 6640 2222
B/4 Laxmi Towers, Bandra Kurla Complex
Mumbai, 400 051
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.